Dihydroergotamine Nasal Spray [Regulatives / Guidelines]

posted by Helmut Homepage – Vienna, Austria, 2019-06-26 12:10 (1756 d 03:37 ago) – Posting: # 20361
Views: 2,557

Hi NK,

❝ The guidance specified that "baseline corrected PK data of AUC and Cmax should be used for bio-equivalence calculation"

❝ As per my understanding, Dihydroergotamine is neither endogenous …


Correct.

❝ … nor available in the diet, …


Oh yes! Even when, it would practically not absorbed.

❝ … then why baseline value is required?


IMHO, a bizarre idea. Ask the FDA.

❝ If it is required, …


It is. If you would deviate from a guidance without a controlled correspondence you risk an RtR.

❝ … what should be baseline sampling time points (-1h or -30 min or -15 min ...)?


The FDA’s general approach for a stable baseline is subtracting the mean of {-1 h, -0.5 h, pre-dose}. In your case likely it would be BQL anyhow. ;-)

Dif-tor heh smusma 🖖🏼 Довге життя Україна! [image]
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

UA Flag
Activity
 Admin contact
22,984 posts in 4,822 threads, 1,651 registered users;
61 visitors (0 registered, 61 guests [including 7 identified bots]).
Forum time: 15:48 CEST (Europe/Vienna)

You can’t fix by analysis
what you bungled by design.    Richard J. Light, Judith D. Singer, John B. Willett

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5